Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India; School of Public Health, Faculty of Health, University of Technology Sydney, PO Box 123, Broadway, NSW 2007, Australia.
Cell Signal. 2024 Dec;124:111452. doi: 10.1016/j.cellsig.2024.111452. Epub 2024 Oct 5.
Cerebral ischemic injury is characterized by reduced blood flow to the brain, remains a significant cause of morbidity and mortality worldwide. Despite improvements in therapeutic approaches, there is an urgent need to identify new targets to lessen the effects of ischemic stroke. Aquaporins, a family of water channel proteins, have recently come to light as promising candidates for therapeutic intervention in cerebral ischemic injury. There are 13 aquaporins identified, and AQP4 has been thoroughly involved with cerebral ischemia as it has been reported that modulation of AQP4 activity can offers a possible pathway for therapeutic intervention along with their role in pH, osmosis, ions, and the blood-brain barrier (BBB) as possible therapeutic targets for cerebral ischemia injury. The molecular pathways which can interacts with particular cellular pathways, participation in neuroinflammation, and possible interaction with additional proteins thought to be involved in the etiology of a stroke. Understanding these pathways offers crucial information on the diverse role of AQPs in cerebral ischemia, paving the door for the development of focused/targeted therapeutics.
脑缺血损伤的特征是脑血流量减少,仍然是全世界发病率和死亡率的重要原因。尽管治疗方法有所改进,但仍迫切需要确定新的靶点,以减轻缺血性中风的影响。水通道蛋白是一类水通道蛋白,最近被认为是治疗脑缺血损伤的有希望的候选药物。已经确定了 13 种水通道蛋白,AQP4 与脑缺血密切相关,因为据报道,调节 AQP4 活性可以为治疗干预提供一条可能的途径,其在 pH 值、渗透压、离子和血脑屏障 (BBB) 中的作用也可能是脑缺血损伤的治疗靶点。可以与特定细胞途径相互作用的分子途径、参与神经炎症以及与可能涉及中风病因的其他蛋白质的可能相互作用。了解这些途径为 AQP 在脑缺血中的多种作用提供了关键信息,为有针对性的治疗药物的开发铺平了道路。
Psychopharmacol Bull. 2024-7-8
Curr Neurol Neurosci Rep. 2025-7-1
2025-1
Arch Ital Urol Androl. 2025-6-30
Biomedicines. 2025-6-7
1993
Inflammopharmacology. 2025-6-23
Mol Biol Rep. 2025-4-9
Cancer Immunol Immunother. 2025-4-1